FDA Approves Nexlizet (bempedoic acid and ezetimibe) to Lower LDL-Cholesterol

ANN ARBOR, Mich., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the U.S. Food and Drug Administration (FDA) approved Nexlizet (bempedoic acid and ezetimibe) tablet, an oral, once-daily, non-statin LDL-Cholesterol...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news